Other languages BeyondSpring Inc.

Equities

BYSI

KYG108301006

Market Closed - Nasdaq Other stock markets 21:00:00 26/04/2024 BST			5-day change	1st Jan Change
2.13 ^USD	-6.17%		+11.52%	+136.67%

04-22	North American Morning Briefing : Stock Futures -2-	DJ
04-15	North American Morning Briefing : Stock Futures -2-	DJ

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BeyondSpring Says First Patient Dosed in Phase 2 Trial of Lung Cancer Combination Treatment	03-25
Beyondspring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in A Phase 2 Investigator-Initiated Study of First-Line Extensive-Stage Small-Cell Lung Cancer	03-25
BeyondSpring Inc. Announces Executive Changes	03-18
Top Premarket Decliners	03-06
BeyondSpring Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	02-02
BeyondSpring Receives Non-Compliance Notice From Nasdaq	01-10
BeyondSpring Receives Notification From Nasdaq for Breaching Minimum Bid Price Requirements	12-19
BeyondSpring Inc. Announces New Data That Translates Preclinical Proof-Of-Concept to Clinical Evidence of Plinabulin?s Immunomodulating Activity	11-07
BeyondSpring Inc. Announces Retirement of Yanbin Xie as Board of Director	14/07/23
BeyondSpring Inc. Announces New Data from Phase 1 Investigator Initiated Study Plinabulin’s Ability to Reduce Infectious Neutropenic Fever for Multiple Myeloma Patients Undergoing AHCT	07/06/23
BeyondSpring Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	18/04/23
BeyondSpring Inc. Auditor Raises 'Going Concern' Doubt	17/04/23
BeyondSpring Inc. Enrolls First Patient in Phase 2 Study with Plinabulin, Keytruda and Docetaxel in Patients with Metastatic Non-Small Cell Lung Cancer Who Progressed After Immunotherapy	01/03/23
BeyondSpring Inc. Reports Earnings Results for the Half Year Ended June 30, 2022	28/02/23
Ramon Mohanlal Left Beyondspring Inc. as the Chief Medical Officer and Executive Vice President	24/02/23
BeyondSpring Regains Compliance With Nasdaq's Minimum Bid Price Rule; Gets New Non-Compliance Notice for Delayed Filing	10/01/23
BeyondSpring Inc. Announces the Resignation of Christine Ying Zhao from the Board of Directors, Effective January 1, 2023	30/12/22
Sector Update: Health Care Stocks Flat To Higher Premarket Friday	25/11/22
BeyondSpring Inc. Presents New Clinical Evidence of Plinabulin Protection of Granulocyte-Monocyte Progenitor Stem Cells for the Prevention of Chemotherapy-Induced Neutropenia at the ESMO Congress 2022	13/09/22
BeyondSpring Inc. Announces Board Appointments	29/08/22

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages BeyondSpring Inc.

Equities

BYSI

KYG108301006

Other languages

Filters